Drug Trial Radar · NCT01422915
Sorbent Therapy of the Cutaneous Porphyrias
Last checked: Nov 20, 2026Latest source record: Apr 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
May 2011
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 22 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).
Conditions
- Erythropoietic Protoporphyria
Interventions
ColestipolDrug
2 grams morning and bedtime for 90 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Photosensitivity, Assessed by Measuring the Number of Minutes of Sun ToleranceTime frame: At 60 days of treatment
- Protoporphyrin Concentration in BloodTime frame: Samples collected while on treatment (range 93-208 treatment days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham & Women's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.